Skip to main content
Search
Search
    Quick Search anywhere
    Quick search in Citations
Advanced Search
Skip main navigationClose Drawer MenuOpen Drawer Menu
Next article
Open AccessReview

Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease

European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement

Published Online:November 08, 2021https://doi.org/10.1024/0301-1526/a000969

Abstract

Summary: Patients with peripheral arterial disease (PAD) are at very high risk of cardiovascular events, but risk factor management is usually suboptimal. This Joint Task Force from the European Atherosclerosis Society and the European Society of Vascular Medicine has updated evidence on the management on dyslipidaemia and thrombotic factors in patients with PAD. Guidelines recommend a low-density lipoprotein cholesterol (LDLC) goal of more than 50% reduction from baseline and <1.4 mmol/L (<55 mg/dL) in PAD patients. As demonstrated by randomized controlled trials, lowering LDL-C not only reduces cardiovascular events but also major adverse limb events (MALE), including amputations, of the order of 25%. Addition of ezetimibe or a PCSK9 inhibitor further decreases the risk of cardiovascular events, and PCSK9 inhibition has also been associated with reduction in the risk of MALE by up to 40%. Furthermore, statin- based treatment improved walking performance, including maximum walking distance, and pain-free walking distance and duration. This Task Force recommends strategies for managing statin-associated muscle symptoms to ensure that PAD patients benefit from lipid-lowering therapy. Antiplatelet therapy, either daily clopidogrel 75 mg or the combination of aspirin 100 mg and rivaroxaban (2×2.5 mg) is also indicated to prevent cardiovascular events. Dual pathway inhibition (aspirin and rivaroxaban) may be considered following revascularization, taking into account bleeding risk. This Joint Task Force believes that adherence with these recommendations for lipid-lowering and antithrombotic therapy will improve the morbidity and mortality in patients with PAD.

References

  • 1 Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004;172:95–105. First citation in articleCrossref Medline, Google Scholar

  • 2 Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–40. First citation in articleCrossref Medline, Google Scholar

  • 3 Sartipy F, Sigvant B, Lundin F, Wahlberg E. Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome. Eur J Vasc Endovasc Surg. 2018;55:529–36. First citation in articleCrossref Medline, Google Scholar

  • 4 Chen DC, Singh GD, Armstrong EJ, Waldo SW, Laird JR, Amsterdam EA. Long-term comparative outcomes of patients with peripheral artery disease with and without concomitant coronary artery disease. Am J Cardiol. 2017;119:1146–52. First citation in articleCrossref Medline, Google Scholar

  • 5 Welten GMJM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R, van Domburg RT, et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008;51:1588–96. First citation in articleCrossref Medline, Google Scholar

  • 6 American Cancer Society. Cancer Facts & Figures 2019. Available from https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html. Atlanta: American Cancer Society; 2019. First citation in articleGoogle Scholar

  • 7 Droz-Perroteau C, Blin P, Dureau-Pournin C, Thomas D, Danchin N, Tricoire J, et al. Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI. Therapie. 2019;74:459–68. First citation in articleCrossref Medline, Google Scholar

  • 8 Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71:510–5. First citation in articleCrossref Medline, Google Scholar

  • 9 Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003;163:884–92. First citation in articleCrossref Medline, Google Scholar

  • 10 Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–6. First citation in articleCrossref Medline, Google Scholar

  • 11 Reinecke H, Unrath M, Freisinger E, Bunzemeier H, Meyborg M, Luders F, et al. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart J. 2015;36:932–8. First citation in articleCrossref Medline, Google Scholar

  • 12 Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier PH, et al. ESVM guideline on peripheral arterial disease. VASA. 2019;48:1–79. First citation in articleLink, Google Scholar

  • 13 Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018;39(4):1131–43. First citation in articleCrossref Medline, Google Scholar

  • 14 Rein P, Saely CH, Silbernagel G, Vonbank A, Mathies R, Drexel H, et al. Systemic inflammation is higher in peripheral artery disease than in stable coronary artery disease. Atherosclerosis. 2015;239:299–303. First citation in articleCrossref Medline, Google Scholar

  • 15 Silbernagel G, Rein P, Saely CH, Engelberger RP, Willenberg T, Do D-D, et al. Prevalence of type 2 diabetes is higher in peripheral artery disease than in coronary artery disease patients. Diab Vasc Dis Res. 2015;12:146–9. First citation in articleCrossref Medline, Google Scholar

  • 16 Tunstall-Pedoe H, Peters SAE, Woodward M, Struthers AD, Belch JJF. Twenty-year predictors of peripheral arterial disease compared with coronary heart disease in the Scottish Heart Health Extended Cohort (SHHEC). J Am Heart Assoc. 2017;6. First citation in articleCrossref Medline, Google Scholar

  • 17 Rizzo M, Pernice V, Frasheri A, Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. Atherosclerosis. 2008;197:237–41. First citation in articleCrossref Medline, Google Scholar

  • 18 Boren J, Williams KJ, The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016;27:473–83. First citation in articleCrossref Medline, Google Scholar

  • 19 Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–72. First citation in articleCrossref Medline, Google Scholar

  • 20 Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41:2313–30. First citation in articleCrossref Medline, Google Scholar

  • 21 Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547–63. First citation in articleCrossref Medline, Google Scholar

  • 22 Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC health promotion series. J Am Coll Cardiol. 2018;72:1141–56. First citation in articleCrossref Medline, Google Scholar

  • 23 Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21:305–11. First citation in articleCrossref Medline, Google Scholar

  • 24 Johansson L, Schmidt C. Increased apoB/apoA-I ratio is predictive of peripheral arterial disease in initially healthy 58-year-old men during 8.9 years of follow-up. Angiology. 2009;60:539–45. First citation in articleCrossref Medline, Google Scholar

  • 25 Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, et al. Genome-wide association study of peripheral artery disease in the Million Veteran Program. Nat Med. 2019;25:1274–9. First citation in articleCrossref Medline, Google Scholar

  • 26 Gudbjartsson DF, Thorgeirsson G, Sulem P, Helgadottir A, Gylfason A, Saemundsdottir J, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74:2982–94. First citation in articleCrossref Medline, Google Scholar

  • 27 Joosten MM, Pai JK, Bertoia ML, Rimm EB, Spiegelman D, Mittleman MA, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012;308:1660–7. First citation in articleCrossref Medline, Google Scholar

  • 28 Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509–26. First citation in articleCrossref Medline, Google Scholar

  • 29 Aday AW, Lawler PR, Cook NR, Ridker PM, Mora S, Pradhan AD. Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence. Circulation. 2018;138:2330–41. First citation in articleCrossref Medline, Google Scholar

  • 30 Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88. First citation in articleCrossref Medline, Google Scholar

  • 31 Annemans L, Packard CJ, Briggs A, Ray KK. “Highest risk-highest benefit” strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. Eur Heart J. 2018;39:2546–50. First citation in articleCrossref Medline, Google Scholar

  • 32 McDermott MM, Mandapat AL, Moates A, Albay M, Chiou E, Celic L, et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arch Intern Med. 2003;163:2157–62. First citation in articleCrossref Medline, Google Scholar

  • 33 Dopheide JF, Papac L, Schindewolf M, Baumgartner I, Drexel H. Poor attainment of lipid targets in patients with symptomatic peripheral artery disease. J Clin Lipidol. 2018;12:711–7. First citation in articleCrossref Medline, Google Scholar

  • 34 Kuiper JG, Sanchez RJ, Houben E, Heintjes EM, Penning-van Beest FJA, Khan I, et al. Use of lipid-modifying therapy and LDL-C goal attainment in a high-cardiovascular-risk population in the Netherlands. Clin Ther. 2017;39:819–27.e1. First citation in articleCrossref Medline, Google Scholar

  • 35 Teramoto T, Uno K, Miyoshi I, Khan I, Gorcyca K, Sanchez RJ, et al. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan. Atherosclerosis. 2016;251:248–54. First citation in articleCrossref Medline, Google Scholar

  • 36 Aung PP, Maxwell H, Jepson RG, Price J, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007. First citation in articleCrossref Medline, Google Scholar

  • 37 Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e686–725. First citation in articleMedline, Google Scholar

  • 38 Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the 2017 European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816. First citation in articleCrossref Medline, Google Scholar

  • 39 Pastori D, Farcomeni A, Milanese A, Del Sole F, Menichelli D, Hiatt WR, et al. Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost. 2020;120:866–75. First citation in articleCrossref Medline, Google Scholar

  • 40 Kokkinidis DG, Arfaras-Melainis A, Giannopoulos S, Katsaros I, Jawaid O, Jonnalagadda AK, et al. Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: A systematic review and meta-analysis. Vasc Med. 2020;25:106–17. First citation in articleCrossref Medline, Google Scholar

  • 41 Castaño G, Más R, Fernández L, Gámez R, Illnait J. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. Angiology. 2003;54:25–38. First citation in articleCrossref Medline, Google Scholar

  • 42 Mohler ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481–6. First citation in articleCrossref Medline, Google Scholar

  • 43 Heart Protection Study Collaborative Group, Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, et al. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol. 2007;49:311–9. First citation in articleCrossref Medline, Google Scholar

  • 44 Ramos R, García-Gil M, Comas-Cufí M, Quesada M, Marrugat J, Elosua R, et al. Statins for prevention of cardiovascular events in a low-risk population with low ankle brachial index. J Am Coll Cardiol. 2016;67:630–40. First citation in articleCrossref Medline, Google Scholar

  • 45 Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol. 2003;92:711–2. First citation in articleCrossref Medline, Google Scholar

  • 46 Kuritz SJ, Landis JR, Koch GG. A general overview of Mantel-Haenszel methods: applications and recent developments. Annu Rev Public Health. 1988;9:123–60. First citation in articleCrossref Medline, Google Scholar

  • 47 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. First citation in articleCrossref Medline, Google Scholar

  • 48 Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol. 1998;81:333–5. First citation in articleCrossref Medline, Google Scholar

  • 49 Weir-McCall JR, White RD, Ramkumar PG, Gandy SJ, Khan F, Belch JJF, et al. Follow-up of atheroma burden with sequential whole body contrast enhanced MR angiography: a feasibility study. Int J Cardiovasc Imaging. 2016;32:825–32. First citation in articleCrossref Medline, Google Scholar

  • 50 Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. 2009;38:463–74. First citation in articleCrossref Medline, Google Scholar

  • 51 Bregar U, Poredos P, Sabovic M, Jug B, Sebestjen M. The influence of atorvastatin on walking performance in peripheral arterial disease. VASA. 2009;38:155–9. First citation in articleLink, Google Scholar

  • 52 Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114:359–64. First citation in articleCrossref Medline, Google Scholar

  • 53 Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97. First citation in articleCrossref Medline, Google Scholar

  • 54 Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park J-G, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6:934–43. First citation in articleCrossref Medline, Google Scholar

  • 55 Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22. First citation in articleCrossref Medline, Google Scholar

  • 56 Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107. First citation in articleCrossref Medline, Google Scholar

  • 57 Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137:338–50. First citation in articleCrossref Medline, Google Scholar

  • 58 Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;74:1167–76. First citation in articleCrossref Medline, Google Scholar

  • 59 Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, et al. Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation. 2020;141:1608–17. First citation in articleCrossref Medline, Google Scholar

  • 60 Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019;124:328–50. First citation in articleCrossref Medline, Google Scholar

  • 61 Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012–22. First citation in articleCrossref Medline, Google Scholar

  • 62 Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96–103. First citation in articleCrossref Medline, Google Scholar

  • 63 Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–14. First citation in articleCrossref Medline, Google Scholar

  • 64 Lotteau S, Ivarsson N, Yang Z, Restagno D, Colyer J, Hopkins P, et al. A mechanism for statin-induced susceptibility to myopathy. JACC Basic Transl Sci. 2019;4:509–23. First citation in articleCrossref Medline, Google Scholar

  • 65 Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6:208–15. First citation in articleCrossref Medline, Google Scholar

  • 66 Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940–8. First citation in articleCrossref Medline, Google Scholar

  • 67 Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526–34. First citation in articleCrossref Medline, Google Scholar

  • 68 Narula N, Dannenberg AJ, Olin JW, Bhatt DL, Johnson KW, Nadkarni G, et al. Pathology of peripheral artery disease in patients with critical limb ischemia. J Am Coll Cardiol. 2018;72:2152–63. First citation in articleCrossref Medline, Google Scholar

  • 69 Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–30. First citation in articleCrossref Medline, Google Scholar

  • 70 Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301:1909–19. First citation in articleCrossref Medline, Google Scholar

  • 71 Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2 P-TIMI 50. Circulation. 2013;127:1522–9.9e1-6. First citation in articleCrossref Medline, Google Scholar

  • 72 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86. First citation in articleCrossref Medline, Google Scholar

  • 73 Caprie Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–39. First citation in articleCrossref Medline, Google Scholar

  • 74 Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30:192–201. First citation in articleCrossref Medline, Google Scholar

  • 75 Belch JJ, Dormandy J, CASPAR Writing Committee, Biasi GM, Cairols M, Diehm C, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52:825–33.e1-2. First citation in articleCrossref Medline, Google Scholar

  • 76 Franzone A, Piccolo R, Gargiulo G, Ariotti S, Marino M, Santucci A, et al. Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial. JAMA Cardiol. 2016;1:795–803. First citation in articleCrossref Medline, Google Scholar

  • 77 Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016;67:2719–28. First citation in articleCrossref Medline, Google Scholar

  • 78 Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:219–29. First citation in articleCrossref Medline, Google Scholar

  • 79 Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018;71:2306–15. First citation in articleCrossref Medline, Google Scholar

  • 80 Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382:1994–2004. First citation in articleCrossref Medline, Google Scholar